The Inflammatory Bowel Disease (IBD) Panel, which includes NOD2, IL23R, and ATG16L1 genes along with CYP2C19, which are associated with IBD severity and susceptibility can aid in defining genetic risk and tailoring treatment for patients suffering from Crohn’s disease and ulcerative colitis (Slavin et al., 2019). The gene discussed is CYP2C19; the disease is inflammatory bowel disease.